Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease

D. Ramirez-Montealegre, S. Chattopadhyay, T. M. Curran, C. Wasserfall, L. Pritchard, D. Schatz, J. Petitto, D. Hopkins, J. X. She, P. G. Rothberg, M. Atkinson, David A. Pearce

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The pathogenic mechanisms underlying Batten disease are unclear. Patients uniformly possess autoantibodies against glutamic acid decarboxylase (GAD) that are predominantly reactive with a region of GAD (amino acids 1 to 20) distinct from subjects with autoimmune type 1 diabetes or stiff-person syndrome. Batten patients did not possess autoantibodies against other type 1 diabetes-associated autoantigens and human leukocyte antigen genotypes revealed no specific associations with this disease.

Original languageEnglish (US)
Pages (from-to)743-745
Number of pages3
JournalNeurology
Volume64
Issue number4
DOIs
StatePublished - Feb 22 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease'. Together they form a unique fingerprint.

Cite this